Treatment with the dual-incretin agonist DA-CH5 demonstrates potent therapeutic effect in a rat model of Wolfram Syndrome
Frontiers in Endocrinology · 2023
DOI: 10.3389/fendo.2023.1234925 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Endocrinology, 2023. Verfasst von Toomas Jagomäe und 8 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory Animal Centre, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia. Hauptthemen laut MEDLINE: Wolfram Syndrome, Insulin-Secreting Cells. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Aim
Wolfram Syndrome (WS) is a rare condition caused by mutations in Wfs1 , with a poor prognosis and no cure. Mono-agonists targeting the incretin glucagon-like-peptide 1 (GLP-1) have demonstrated disease-modifying potential in pre-clinical and clinical settings. Dual agonists that target GLP-1 and glucose-dependent insulinotropic polypeptide (GIP-1) are reportedly more efficacious; hence, we evaluated the therapeutic potential of dual incretin agonism in a loss-of-function rat model of WS.
Methods
Eight-month-old Wfs1 knock-out (KO) and wild-type control rats were continuously treated with either the dual agonist DA-CH5 or saline for four months. Glycemic profile, visual acuity and hearing sensitivity were longitudinally monitored pre-treatment, and then at 10.5 and 12 months. Pancreata and retina were harvested for immunohistological analysis.
Results
DA-CH5 therapy reversed glucose intolerance in KO rats and provided lasting anti-diabetogenic protection. Treatment also reversed intra-islet alterations, including reduced endocrine islet area and β-cell density, indicating its regenerative potential. Although no rescue effect was noted for hearing loss, visual acuity and retinal ganglion cell density were better preserved in DA-CH5-treated rats.
Conclusion
We present preclinical evidence for the pleiotropic therapeutic effects of long-term dual incretin agonist treatment; effects were seen despite treatment beginning after symptom-onset, indicating reversal of disease progression. Dual incretins represent a promising therapeutic avenue for WS patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory Animal Centre, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.
- Eye Clinic of Tartu University Hospital, Tartu, Estonia.
- Ear Clinic of Tartu University Hospital, Tartu, Estonia.
- Department of Pharmacology, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.
- Department of Physiology, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.
Zitieren
APA
Jagomäe, T., Gaur, N., Seppa, K., Reimets, R., Pastak, M., Plaas, M., Kaasik, A., Vasar, E., & Plaas, M. (2023). Treatment with the dual-incretin agonist DA-CH5 demonstrates potent therapeutic effect in a rat model of Wolfram Syndrome. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2023.1234925
Vancouver
Jagomäe T, Gaur N, Seppa K, Reimets R, Pastak M, Plaas M, et al. Treatment with the dual-incretin agonist DA-CH5 demonstrates potent therapeutic effect in a rat model of Wolfram Syndrome. Frontiers in Endocrinology. 2023. doi:10.3389/fendo.2023.1234925
BibTeX
@article{Jagome2023,
author = {Jagomäe, Toomas and Gaur, Nayana and Seppa, Kadri and Reimets, Riin and Pastak, Marko and Plaas, Mihkel and Kaasik, Allen and Vasar, Eero and Plaas, Mario},
title = {Treatment with the dual-incretin agonist DA-CH5 demonstrates potent therapeutic effect in a rat model of Wolfram Syndrome},
journal = {Frontiers in Endocrinology},
year = {2023},
doi = {10.3389/fendo.2023.1234925}
}
EUVIMED